CDKN2A and cancer: Fu et al.’s analysis of 410 cancer-associated gene copy numbers from a patient with IS identified PDGFRA, MDM2, KIT genomic amplification, and CDKN2A and CDKN2B deletions in that case, confirming the emerging concept of considering PDGFR signaling as a diagnostic biomarker specific for IS (11).